Ophthotech gains gene therapy for orphan vision-loss disease

By Jennie Walters | Jun 7, 2018 | 8:58 PM GMT

Ophthotech Corp. (NASDAQ:OPHT) gained $0.29 (10%) to $3.09 on Thursday on news that it acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research